SCHEMBL28447463

SCHEMBL28447463

CC(C)(C)OC(=O)NC1CC(=O)Nc2ccccc2C1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.69
BRD4 O60885 7/20 0.50
CREBBP Q92793 6/20 0.50
MAPK10 P53779 1/20 0.44
DRD2 P14416 2/20 0.44
KDM1A O60341 1/20 0.44
MAOB P27338 1/20 0.44
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GAA P10253 1/20 0.42
EP300 Q09472 1/20 0.41
NAMPT P43490 1/20 0.41
PIM1 P11309 1/20 0.41
PIM3 Q86V86 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
BUB1 O43683 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29500871 0.86 EPHX2 (0.67) EPHX2MAPK10DRD2KDM1AMAOB
SCHEMBL28451186 0.84 EPHX2 (0.49) EPHX2BRD4CREBBPDRD2KDM1A
SCHEMBL29500912 0.84 EPHX2 (0.49) EPHX2BRD4CREBBPDRD2KDM1A
SCHEMBL173219 0.83 EPHX2 (0.69) EPHX2DRD2KDM1AMAOBKMT2A
SCHEMBL31694392 0.83 EPHX2 (0.69) EPHX2DRD2KDM1AMAOBKMT2A
SCHEMBL28454474 0.83 EPHX2 (0.48) EPHX2BRD4CREBBPDRD2KMT2A
SCHEMBL29500783 0.83 EPHX2 (0.48) EPHX2BRD4CREBBPDRD2KMT2A
SCHEMBL29500902 0.83 EPHX2 (0.48) EPHX2BRD4CREBBPKDM1AMAOB
SCHEMBL29500985 0.83 EPHX2 (0.48) EPHX2BRD4CREBBPKDM1AMAOB
SCHEMBL28451195 0.83 EPHX2 (0.48) EPHX2BRD4CREBBPKDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111479813-B Triazolobenzazepines as vasopressin V1A receptor antagonists 吉瑞工厂 2023-03-21 CN disclosed
EP-3724192-B1 TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2022-08-03 EP disclosed
US-11298363-B2 Triazolobenzazepines as vasopressin V1a receptor antagonists RICHTER GEDEON NYRT. (HU) 2022-04-12 US disclosed
CN-111479813-A Triazolobenzazepines as vasopressin V1A receptor antagonists 吉瑞工厂 2020-07-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11298363-B2 Triazolobenzazepines as vasopressin V1a receptor antagonists AVPR1B, AVPR1A, AVPR2 EPHX2 2042/4885BRD4 1235/4885CREBBP 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.